Verteporfin in photodynamic therapy (VIP) study group

Intravitreal Ranibizumab for Choroidal Neovascularization Complicating Pathologic Myopia

“…Choroidal neovascularization secondary to pathologic myopia is the most common cause of CNV in young patients, accounting for up to 60% of CNV in those aged Յ50 years. Different treatments of CNV secondary to pathologic myopia have been evaluated in different consecutive prospective or retrospective interventional series, including direct laser photocoagulation, 1-4 photodynamic therapy (PDT), [5][6][7][8][9] surgical removal, 10 -16 or macular translocation. 17,18 Photodynamic therapy, surgical removal of CNV, or macular translocation are actually associated with better visual outcomes than natural history.…”

Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization

“…The myopic CNV lesion often manifests in a classic pattern of leakage on FA, with early hyperfluorescence that increases in size and intensity in later phases. 22 , 25 , 26 Compared to classic CNV associated with age-related macular degeneration, myopic CNV tends to demonstrate less pronounced leakage, 27 which at times can present a challenge when attempting to differentiate fluorescein leakage from staining.…”

Combined therapy (intravitreal bevacizumab plus verteporfin photodynamic therapy) versus intravitreal bevacizumab monotherapy for choroidal neovascularization due to age-related macular degeneration: a 1-year follow-up study

“…Until recently, few therapeutic options were available for the treatment of AMD-associated CNV, the main treatments being photodynamic therapy (PDT) with verteporfin and intravitreal administrations of pegaptanib sodium (Macugen; Eyetech Inc, Cedar Knolls, NJ) or triamcinolone (Kanacort; Bristol-Myers Squibb, NJ). [2][3][4][5][6][7][8][9] Recently develop-ments in producing humanized mouse monoclonal antibodies that bind all vascular endothelial growth factor (VEGF) isoforms has offered a new means to treat CNV due to AMD. Ranibizumab (Lucentis; Genentech, South San Francisco, CA), a Food and Drug Administrationapproved monoclonal antibody that blocks VEGF, provides an effective treatment for neovascular AMD.…”